Patent Application
20200010814
The present invention relates to a novel monooxygenase, a gene encoding the same, and use thereof.
An optically active α,α-disubstituted amino acid increases the stability against a peptidase, and is promising as a building block of a peptide pharmaceutical drug (see Non-Patent Literature 1).
An optically active α,α-disubstituted amino acid may be produced by, for example, a method disclosed in Non-Patent Literature 2, that is, a method for producing an optically active α,α-disubstituted amino acid through asymmetric alkylation involving use of chiral phase-transfer catalysts. Further, Patent Literature 1 discloses a reaction for synthesizing α-methyl-L-serine through an enzymatic reaction based on L-alanine and formaldehyde as ingredients.
[Patent Literature 1]
Japanese Patent No. 4877227 (Publication Date: Feb. 15, 2012)
[Non-Patent Literature 1]
Claudio Mapelli et al., J. Med. Chem., 2009, 52, 7788-7799.
[Non-Patent Literature 2]
Takashi Ooi et al., J. Am. Chem. Soc., 2003, 125, 5139-5151
The method disclosed in Non-Patent Literature 2 allows an optically active α,α-disubstituted amino acid to be produced, but unfortunately requires complicated steps such as introduction of a protecting group and deprotecting after reaction. The method disclosed in Patent Literature 1 does not require a protecting group, but only allows α-methyl-L-serine (L form) to be synthesized, and does not allow α-methyl-D-serine (which is an optical isomer of α-methyl-L-serine) to be synthesized.
There has thus been a demand for an improved method for simply and efficiently producing an optically active α,α-disubstituted amino acid, for example, optically active α-methyl-D-serine.
In view of the above, it is an object of the present invention to provide a novel enzyme protein that allows production of a β-hydroxyamino acid including an optically active α,α-disubstituted amino acid, for example, production of α-methyl-D-serine.
The inventor of the present invention conducted diligent research for attaining the above object, and thereby succeeded in isolating a microorganism in the natural world which microorganism has the ability to convert 2-aminoisobutyric acid into optically active α-methyl-D-serine. The inventor also succeeded in, through proteome analysis and various analyses related thereto of the microorganism, identifying a novel monooxygenase for converting 2-aminoisobutyric acid into α-methyl-D-serine. Further, as the inventor analyzed the identified novel monooxygenase in detail, the inventor discovered that even in a case where the substrate is L-isovaline, D-isovaline, L-aminobutyrate, D-aminobutyrate, or the like, the monooxygenase has activity for conversion of an α-amino acid or α,α-disubstituted amino acid into an optically active β-hydroxyamino acid. The inventor has thus completed the present invention. Therefore, the present invention has the aspects below.
[1] A monooxygenase, including: two kinds of hetero subunits. In some embodiments, the monooxygenase may be isolated. In other embodiments, the monooxygenase may be purified. Illustratively, the monooxygenase is a purified monooxygenase having a level of purity, and the purity may be not less than about 70%, not less than about 75%, not less than about 80%, not less than about 85%, not less than about 90%, not less than about 91%, not less than about 92%, not less than about 93%, not less than about 94%, not less than about 95%, not less than about 96%, not less than about 97%, not less than about 98%, or not less than about 99%.
[2] The monooxygenase according to [1], wherein
[3] The monooxygenase according to [2], wherein the α-amino acid or α,α-disubstituted amino acid is a compound represented by Formula (1) below:
[4] The monooxygenase according to any one of [1] to [3], wherein
[5] The monooxygenase according to any one of [1] to [4], wherein
[6] A monooxygenase reaction system for producing a β-hydroxyamino acid, the system including: a monooxygenase according to any one of [1] to [5]; and an electron transport chain protein. In some embodiments, the monooxygenase reaction system is an isolated or purified system.
[7] The monooxygenase reaction system according to [6], wherein
[8] A monooxygenase gene encoding a protein recited in any one of [1] to [5]. In some embodiments, the monooxygenase gene is an isolated or purified gene.
[9] A recombinant vector, including: a gene according to [8].
[10] A transformant, including: a gene according to [8]; or a recombinant vector according to [9]. In some embodiments, the transformant is an isolated or purified transformant.
[11] The transformant according to [10], further including:
[12] The transformant according to [11], wherein
[13] The transformant according to [11] or [12], wherein
[14] The transformant according to any one of [10] to [13], wherein
[15] A method for producing a β-hydroxyamino acid, the method including the step of:
[16] The method according to [15], wherein
[17] A Rhodococcus wratislaviensis C31-06 strain with an accession number of NITE BP-02370.
An aspect of the present invention allows an α-amino acid or α,α-disubstituted amino acid to be converted into a β-hydroxyamino acid simply and efficiently while the aspect does not require steps such as introduction of a protecting group or deprotecting.
The following description will discuss an embodiment of the present invention in detail. All academic and patent documents cited in the present specification are incorporated herein by reference. Further, any numerical range expressed as “A to B” in the present specification means “not less than A and not more than B” unless otherwise stated.
The term “gene” as used herein is interchangeable with “polynucleotide”, “nucleic acid”, and “nucleic acid molecule”, and refers to a polymer of nucleotides. The gene may be in the form of DNA (for example, cDNA or genomic DNA) or RNA (for example, mRNA). The DNA or RNA may be double-stranded or single-stranded. The single-stranded DNA or RNA may be a coding strand (sense strand) or noncoding strand (antisense strand). The gene may be synthesized chemically, or the codon usage may be changed for an increased expression of a protein to be encoded. The gene may have a codon substituted with another codon as long as those codons encode an identical amino acid.
The term “protein” is used interchangeably with “peptide” or “polypeptide”. A base and amino acid are expressed herein as appropriate with a single letter or a three-letter combination defined by the IUPAC and IUB.
<1. Monooxygenase>
An embodiment of the present invention provides a monooxygenase including at least two kinds of hetero (different) subunits (in other words, a hetero monooxygenase including two or more kinds of different subunits).
A monooxygenase is a kind of oxidase, and is an enzyme that introduces a single oxygen atom into a substrate. Conventionally known monooxygenases mostly function as a single enzyme in terms of structure. No monooxygenase has been known such as a monooxygenase including a complex (that is, hetero subunits) as for an embodiment of the present invention. Thus, the discovery of the monooxygenase as an embodiment of the present invention, which monooxygenase has the above structure, is surprising. The monooxygenase is capable of catalyzing a reaction which conventional monooxygenases are incapable of catalyzing or have low reaction activity. An embodiment of the present invention thus provides a new and useful monooxygenase that has been absent conventionally.
A monooxygenase as an embodiment of the present invention preferably includes two kinds of hetero (different) subunits. The number of subunits is not limited to any particular one as long as the subunits have monooxygenase activity even in a case where the subunits have formed a complex together with another subunit(s). The number may be, for example, two, three, four, or five.
For a monooxygenase as an embodiment of the present invention, each subunit may have any structure as long as the subunits have monooxygenase activity even in a case where the subunits have formed a complex together with another subunit(s). The subunits may each be, for example, a monomer, a dimer, a trimer, or a tetramer. A monooxygenase as an embodiment of the present invention may include, for example, a heterodimer, a heterotrimer, a heterotetramer, a heteropentamer, and/or a heterohexamer each including the above subunits, as long as the monooxygenase has monooxygenase activity.
A monooxygenase as an embodiment of the present invention has details that are changeable as appropriate as long as the monooxygenase has a characteristic structure described above. Needless to say, a monooxygenase having details that have been changed is also within the scope of the present invention.
A monooxygenase as an embodiment of the present invention is derived from a fungus such as an actinomycete. Example actinomycetes include Rhodococcus and Nocardia. The monooxygenase is derived preferably from Rhodococcus erythropolis, Rhodococcus rhodochrous, Rhodococcus wratislaviensis, or Nocardia globerula, more preferably from Rhodococcus wratislaviensis.
A monooxygenase as an embodiment of the present invention was obtained from a Rhodococcus wratislaviensis C31-06 strain as discussed later for the Examples. The Rhodococcus wratislaviensis C31-06 strain is deposited at the National Institute of Technology and Evaluation (NITE) Patent Microorganisms Depositary (#122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba 292-0818, Japan) (depositor: Makoto Hibi, the Graduate School of Agriculture, Kyoto University [Oiwake-cho, Kitashirakawa, Sakyo-ku, Kyoto-shi, Kyoto 606-8502 Japan], accession number: NITE BP-02370 [accession date (domestic accession date): Oct. 6, 2016; transfer date: Mar. 12, 2018; domestic accession number before transfer: NITE P-02370]). The present invention thus also provides the Rhodococcus wratislaviensis C31-06 strain.
A monooxygenase as an embodiment of the present invention is capable of catalyzing a reaction for converting an α-amino acid or α,α-disubstituted amino acid into an optically active β-hydroxyamino acid. In other words, another preferable embodiment of the present invention is a monooxygenase capable of catalyzing a reaction for converting an α-amino acid or α,α-disubstituted amino acid into an optically active β-hydroxyamino acid, preferably a monooxygenase derived from Rhodococcus and capable of catalyzing a reaction for converting an α-amino acid or α,α-disubstituted amino acid into an optically active β-hydroxyamino acid.
The term “α-amino acid” as used herein refers to an amino acid having a monosubstituted α position. Examples of the α-amino acid for the present embodiment include, but are not limited to, L-aminobutyrate and D-aminobutyrate.
The term “α,α-disubstituted amino acid” as used herein refers to an amino acid having a disubstituted α position. Examples of the α,α-disubstituted amino acid for the present embodiment include, but are not limited to, 2-aminoisobutyric acid, L-isovaline, and D-isovaline.
The term “β-hydroxyamino acid” as used herein refers to an amino acid having a hydroxylated β position, and may be any amino acid in which a substrate such as an α-amino acid and an α,α-disubstituted amino acid has been caused by a monooxygenase as an embodiment of the present invention to have optical activity. Examples of the β-hydroxyamino acid for the present embodiment include α-methyl-D-serine, (2S,3S)-2-methyl threonine, (2R,3R)-2-methyl threonine, L-allo-threonine, and D-allo-threonine. The term “optically active β-hydroxyamino acid” as used herein is synonymous with “β-hydroxyamino acid”.
A monooxygenase as an embodiment of the present invention is presumed to catalyze hydroxylation of a β position of an α-amino acid or α,α-disubstituted amino acid for conversion thereof into a β-hydroxyamino acid. The α-amino acid, α,α-disubstituted amino acid, and β-hydroxyamino acid may be any α-amino acid, α,α-disubstituted amino acid, and β-hydroxyamino acid as long as the monooxygenase converts an α-amino acid or α,α-disubstituted amino acid into an optically active β-hydroxyamino acid through the above action mechanism.
For an embodiment of the present invention, the α-amino acid or α,α-disubstituted amino acid to be converted into a β-hydroxyamino acid by a monooxygenase is preferably a compound represented by Formula (1) below.
In a case where R1 is an alkyl group, the alkyl group may have 1 to 5 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 carbon atom. In a case where R1 is an alkyl group, the alkyl group may be linear, branched, or cyclic, preferably linear.
In a case where R2 is an alkyl group, the alkyl group is similar to R1 above.
The asterisk in the formula may or may not represent an asymmetric carbon atom.
For an embodiment of the present invention, the β-hydroxyamino acid into which an α-amino acid or α,α-disubstituted amino acid is to be converted by a monooxygenase is preferably a compound represented by Formula (2) below.
In a case where R3 is an alkyl group, the alkyl group may have 1 to 5 carbon atoms, preferably 1 to 3 carbon atoms, more preferably 1 carbon atom. In a case where R3 is an alkyl group, the alkyl group may be linear, branched, or cyclic, preferably linear.
In a case where R4 is an alkyl group, the alkyl group is similar to R3 above.
The asterisks in the formula may or may not represent an asymmetric carbon atom. Preferably, either of the two asterisks may be an asymmetric carbon atom. More preferably, both of the two asterisks may be asymmetric carbon atoms.
For an embodiment of the present invention, a monooxygenase preferably catalyzes at least one of the respective reactions represented by Formulae (3) to (7) below which reactions are each for converting an α-amino acid or α,α-disubstituted amino acid into an optically active β-hydroxyamino acid.
A monooxygenase as an embodiment of the present invention is preferably capable of catalyzing the at least one of the respective reactions represented by the formulae above which reactions are each for converting an α-amino acid or α,α-disubstituted amino acid into an optically active β-hydroxyamino acid in such a manner that the resulting β-hydroxyamino acid has an optical purity of not less than 60%, more preferably not less than 80%, even more preferably not less than 85%, particularly preferably not less than 87%.
A monooxygenase as an embodiment of the present invention is preferably arranged such that assuming that the two kinds of hetero subunits are an α subunit and a β subunit, the α subunit includes a protein selected from the group consisting of (a) to (d) below, and the β subunit includes a protein selected from the group consisting of (e) to (h) below,
The protein of (a) above is a protein comprising the amino acid sequence represented by SEQ ID NO: 1. The protein of (e) above is a protein comprising the amino acid sequence represented by SEQ ID NO: 2. Each of the proteins is derived from Rhodococcus wratislaviensis. SEQ ID NO: 1 represents a polypeptide comprising 378 amino acid residues in total, the polypeptide having a Protein ID of “peg.803” labeled in Protein Discover Software (available from Thermo Scientific). SEQ ID NO: 2 represents a polypeptide comprising 373 amino acid residues in total, the polypeptide having a Protein ID of “peg.804” labeled in Protein Discover Software (available from Thermo Scientific).
The respective proteins of (b) and (f) above are each, for example, a functionally equivalent mutant, derivative, variant, allele, homolog, ortholog, or partial peptide of a protein comprising the corresponding one of the respective amino acid sequences represented by SEQ ID NO: 1 and NO: 2 or a fusion protein produced from the above protein and another protein or peptide. The protein (b) is not limited in terms of the detailed sequence as long as a subunit including the protein (b) has monooxygenase activity in a case where the subunit including the protein (b) has formed a complex together with the β subunit. The protein (f) is not limited in terms of the detailed sequence as long as a subunit including the protein (f) has monooxygenase activity in a case where the subunit including the protein (f) has formed a complex together with the α subunit. The number of amino acids that may be deleted, substituted, or added may be any number as long as the monooxygenase maintains the above functions. The number is, however, a number of which amino acids may be deleted, substituted, or added by a publicly known introduction method such as site-directed mutagenesis. The number is preferably not more than five amino acids, more preferably not more than three amino acids (for example, three, two, or one amino acid). The term “mutation” as used herein refers mainly to a mutation introduced artificially by, for example, site-directed mutagenesis, but may also refer to a similar, naturally occurring mutation.
An amino acid residue substituted has preferably been substituted with another amino acid having an amino acid side chain of which the property is similar. Examples of the property of an amino acid side chain include a hydrophobic amino acid (A, I, L, M, F, P, W, Y, V), a hydrophilic amino acid (R, D, N, C, E, Q, G, H, K, S, T), an amino acid having an aliphatic side chain (G, A, V, L, I, P), an amino acid having a hydroxy group-containing side chain (S, T, Y), an amino acid having a sulphur atom-containing side chain (C, M), an amino acid having a carboxylic acid or an amide-containing side chain (D, N, E, Q), an amino acid having a base-containing side chain (R, K, H), and an amino acid having an aromatic side chain (H, F, Y, W) (the parentheses show single-letter expressions of amino acids). A polypeptide is known to maintain its biological activity even in a case where an amino acid sequence included in the polypeptide has been modified through deletion of one or more amino acid residues, addition of one or more amino acid residues, and/or substitution of one or more amino acid residues with another amino acid. An amino acid residue as mutated has more preferably been mutated into an amino acid residue sharing as many properties as possible with the amino acid residue before the mutation.
The expression “functionally equivalent” as used herein indicates that a protein has a biological and/or biochemical function equivalent (that is, identical or similar) to that of the protein of interest. Biological properties include, for example, specificity of a site of expression and the amount of expression. Whether a protein into which a mutation has been introduced has a desired function may be determined by studying whether using that protein as part of a subunit allows the complex to have monooxygenase activity.
The respective proteins of (c) and (g) above are also each intended to be, for example, a functionally equivalent mutant, derivative, variant, allele, homolog, ortholog, or partial peptide of a protein comprising the corresponding one of the respective amino acid sequences represented by SEQ ID NO: 1 and NO: 2 or a fusion protein produced from the above protein and another protein or peptide. The protein (c) is not limited in terms of the detailed sequence as long as a subunit including the protein (c) has monooxygenase activity in a case where the subunit including the protein (c) has formed a complex together with the β subunit. The protein (g) is not limited in terms of the detailed sequence as long as a subunit including the protein (g) has monooxygenase activity in a case where the subunit including the protein (g) has formed a complex together with the α subunit.
An amino acid sequence having a homology means that the amino acid sequence has a sequence identity of at least not less than 80%, preferably not less than 85%, more preferably not less than 90%, even more preferably not less than 95% (for example, not less than 95%, 96%, 97%, 98%, or 99%), with respect to the entire amino acid sequence (or a region necessary for functional expression). The homology of an amino acid sequence may be determined with use of a program for BLASTN (nucleic acid level) or BLASTX (amino acid level) (Altschul et al. J. Mol. Biol., 215: 403-410, 1990). This program is based on the algorithm BLAST by Karlin and Altschul (Proc. Natl. Acad. Sci. USA, 87:2264-2268, 1990, Proc. Natl. Acad. Sci. USA, 90: 5873-5877, 1993). In a case where BLASTN is used to analyze a base sequence, the parameters are set as follows, for example: score=100, wordlength=12. In a case where BLASTX is used to analyze an amino acid sequence, the parameters are set as follows, for example: score=50, wordlength=3. In a case where the Gapped BLAST program is used to analyze an amino acid sequence, the analysis may be carried out as discussed in Altschul et al. (Nucleic Acids Res. 25: 3389-3402, 1997). In a case where BLAST and the Gapped BLAST program are used, the default parameters of each program are used. Specifically how analysis is carried out on the basis of each of the above approaches is publicly known. Addition or deletion (for example, a gap) may be accepted so that a base sequence or amino acid sequence to be compared is aligned in an optimal state.
The term “homology” as used herein refers to the proportion (for example, positive) of the number of amino acid residues sharing a similar property, but more preferably refers to identity, that is, the proportion of the number of identical amino acid residues. The properties of an amino acid are as described above.
For the protein of (d) above, SEQ ID NO: 6 represents a base sequence (open reading frame or ORF) of a gene encoding a protein comprising the amino acid sequence represented by SEQ ID NO: 1. For the protein of (h) above, SEQ ID NO: 7 represents a base sequence (ORF) of a gene encoding a protein comprising the amino acid sequence represented by SEQ ID NO: 2.
The above gene and proteins may each be obtained by a typical method for modifying a polynucleotide. Specifically, substituting, deleting, inserting, and/or adding particular bases of a polynucleotide which bases have genetic information of the protein allows a polynucleotide to be prepared that has genetic information of a desired recombinant protein. Specific examples of a method for converting bases of a polynucleotide include using a commercially available kit (for example, KOD-Plus Site-Directed Mutagenesis Kit [available from Toyobo Co., Ltd.], Transformer Site-Directed Mutagenesis Kit [available from Clontech], or QuickChange Site Directed Mutagenesis Kit [available from Stratagene]) and using polymerase chain reaction. These methods are known to persons skilled in the art.
The gene may consist only of a polynucleotide encoding the protein or may include another base sequence added thereto. A base sequence to be added is not limited to any particular one. Examples of the base sequence to be added include a base sequence encoding a label (for example, histidine tag, Myc tag, or FLAG tag), a fusion protein (for example, streptavidin, cytochrome, GST, GFP, or MBP), a promoter sequence, and a signal sequence (for example, endoplasmic reticulum localization signal sequence or secretion sequence). The site to which such a base sequence is to be added is not limited to any particular one. The site may be, for example, the N-terminus or C-terminus of a protein to be translated.
<2. Monooxygenase Reaction System>
An embodiment of the present invention provides a monooxygenase reaction system for producing a β-hydroxyamino acid, the system including the monooxygenase and an electron transport chain protein.
The monooxygenase reaction system is a system that involves the monooxygenase producing a β-hydroxyamino acid with use of oxidation-reduction power provided by means of an electron transport chain protein. The monooxygenase reaction system is not limited to any particular one as long as monooxygenase reaction system includes the monooxygenase and an electron transport chain protein and produces a β-hydroxyamino acid.
The monooxygenase reaction system may be a system developed inside the body of an organism or a system developed artificially outside the body of an organism. The monooxygenase reaction system is, in view of stability and activity of a monooxygenase protein, preferably a system developed inside the body of an organism.
The development of the monooxygenase reaction system inside the body of an organism may be such that the organism has the system inherently or that the system is artificially introduced into an organism that does not have the system.
The monooxygenase reaction system may be artificially introduced into any target by any method. The monooxygenase reaction system may be introduced by, for example, a method described under <4. Vector> and <5. Transformant> below.
The electron transport chain protein for the monooxygenase reaction system is not limited to any particular one as long as the protein provides oxidation-reduction power for allowing the monooxygenase to have monooxygenase activity.
Examples of the electron transport chain protein include a combination of ferredoxin (for example, a Rieske protein, putidaredoxin, or adrenodoxin) and ferredoxin reductase (for example, flavoprotein reductase, putidaredoxin reductase, or adrenodoxin reductase), a combination of flavodoxin and flavodoxin reductase, and P450 reductase.
An embodiment of the present invention is preferably arranged such that the electron transport chain protein includes a protein selected from the group consisting of (i) to (l) below and a protein selected from the group consisting of (m) to (p) below,
The protein of (i) above is a protein comprising the amino acid sequence represented by SEQ ID NO: 3. The protein of (m) above is a protein comprising the amino acid sequence represented by SEQ ID NO: 4. Each of the proteins is derived from Rhodococcus wratislaviensis. SEQ ID NO: 3 represents a polypeptide comprising 322 amino acid residues in total, the polypeptide having a Protein ID of “peg.801” labeled in Protein Discover Software (available from Thermo Scientific). SEQ ID NO: 4 represents a polypeptide comprising 169 amino acid residues in total, the polypeptide having a Protein ID of “peg.802” labeled in Protein Discover Software (available from Thermo Scientific).
The respective proteins of (j) and (n) above are each, for example, a functionally equivalent mutant, derivative, variant, allele, homolog, ortholog, or partial peptide of a protein comprising the corresponding one of the respective amino acid sequences represented by SEQ ID NO: 3 and NO: 4 or a fusion protein produced from the above protein and another protein or peptide. The protein (j) is not limited in terms of the detailed sequence as long as it has electron transport activity in a case where the protein (j) has been combined with a protein selected from the group consisting of (m) to (p). The protein (n) is not limited in terms of the detailed sequence as long as it has electron transport activity in a case where the protein (n) has been combined with a protein selected from the group consisting of (i) to (l).
The respective proteins of (k) and (o) above are also each intended to be, for example, a functionally equivalent mutant, derivative, variant, allele, homolog, ortholog, or partial peptide of a protein comprising the corresponding one of the respective amino acid sequences represented by SEQ ID NO: 3 and NO: 4 or a fusion protein produced from the above protein and another protein or peptide. The protein (k) is not limited in terms of the detailed sequence as long as it has electron transport activity in a case where the protein (k) has been combined with a protein selected from the group consisting of (m) to (p). The protein (o) is not limited in terms of the detailed sequence as long as it has electron transport activity in a case where the protein (o) has been combined with a protein selected from the group consisting of (i) to (l).
For the protein of (l) above, SEQ ID NO: 8 represents a base sequence (open reading frame or ORF) of a gene encoding a protein comprising the amino acid sequence represented by SEQ ID NO: 3. For the protein of (p) above, SEQ ID NO: 9 represents a base sequence (ORF) of a gene encoding a protein comprising the amino acid sequence represented by SEQ ID NO: 4.
For the present embodiment, the electron transport chain protein is not limited to a protein selected from the group consisting of (i) to (l) and a protein selected from the group consisting of (m) to (p), and may be another protein involved with the electron transport system.
For general descriptions of a gene and proteins (for example, term definitions), reference is made to the descriptions under <1. Monooxygenase>.
<3. Gene>
An embodiment of the present invention provides a monooxygenase gene encoding one of the above proteins.
For the present embodiment, the proteins may be those of which the monooxygenase consists as an embodiment of the present invention described under <1. Monooxygenase>.
<4. Vector>
An embodiment of the present invention provides a vector including the gene described under <3. Gene>. The vector may be an expression vector for expressing the above gene in a host cell to prepare a transformant or a vector for use in producing a recombinant protein.
A base vector as a matrix of the vector may be any of various vectors in common use. The base vector may be, for example, a plasmid, a phage, or a cosmid. An appropriate base vector may be selected according to (i) the cell into which the vector is to be introduced or (ii) the method by which the vector is to be introduced. In other words, the specific kind of vector is not limited to any particular one, and a vector that can be expressed in a host cell is selected as appropriate. A promoter sequence is selected as appropriate according to the kind of host cell to ensure the expression of the gene, and is incorporated in, for example, various plasmids together with the gene for use as an expression vector. Examples of the expression vector include a phage vector, a plasmid vector, a viral vector, a retroviral vector, a chromosomal vector, an episomal vector, and a virus-derived vector (for example, a bacterial plasmid, a bacteriophage, a yeast episome, a yeast chromosome element, and a virus [for example, baculovirus, papovavirus, vaccinia virus, adenovirus, avipoxvirus, pseudorabies virus, herpesvirus, lentivirus, and retrovirus]) as well as a vector derived from a combination thereof (for example, a cosmid and a phagemid).
Example vectors that can be used preferably for bacteria include pQE60, pQE70, pQE80, and pQE9 (available from Qiagen); pTipQC1 (available from Qiagen or Hokkaido System Science) and pTipRT2 (available from Hokkaido System Science); pBS vector, Phagescript vector, Bluescript vector, pNH8A, pNH16A, pNH18A, and pNH46A (available from Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, and pRIT5 (available from Addgene); pRSF (available from MERCK); and pAC (available from NIPPON GENE). Examples of preferable eukaryote vectors include pWLNE0, pSV2CAT, pOG44, pXT1, and pSG (available from Stratagene); and pSVK3, pBPV, pMSG, and pSVL (available from Addgene).
An insert of the gene is preferably linked operably with an appropriate promoter. Other appropriate promoters are promoters known to persons skilled in the art, and are not limited to any particular ones. Examples include lacUV5 promotor, trp promotor, trc promotor, tac promotor, 1pp promotor, tufB promotor, recA promotor, pL promotor, lacI promotor, lacZ promotor, T3 promotor, T7 promotor, SV40 early and late promoters, and a promoter of retrovirus LTR.
The vector preferably further includes a site for transcription initiation, a site for transcription termination, and a transcriptional region including a ribosome-binding site for translation. A matured transcript expressed by a vector construct includes a coding region including (i) transcription initiation AUG at the start of a polypeptide to be translated and (ii) a stop codon appropriately positioned at the end of the polypeptide.
A host into which the vector is to be introduced is not limited to any particular one, and may suitably be any of various cells. Typical examples of an appropriate host include, but are not limited to, bacteria, yeast, filamentous fungi, plant cells, and animal cells. The host cell is cultured in an appropriate medium publicly known in the art and under an appropriate condition publicly known in the art.
The method by which the vector is to be introduced into a host cell (that is, the transformation method) is not limited to any particular one. The method may suitably be a conventionally publicly known one such as calcium phosphate method, liposome method, DEAE-dextran method, microinjection, cationic lipid-mediated transfection, electroporation, transduction, and infection. These methods are discussed in many standard laboratory manuals such as Davis et al., Basic Methods In Molecular Biology (1986).
<5. Transformant>
An embodiment of the present invention provides a transformant including the gene described under <3. Gene> or the recombinant vector described under <4. Vector>. The expression “including a gene or a vector” indicates that the gene or vector has been introduced into a target cell (host cell) by a publicly known genetic engineering approach so that the gene or vector can be expressed. The term “transformant” covers not only a cell, tissue, and organ, but also an individual organism.
The transformant may be prepared (produced) by, for example, a method of transforming the above vector. An organism as a target of the transformation is not limited to any particular one, and may be, for example, any of various organisms listed as examples for the host cell.
Examples of a host cell for use in an embodiment of the present invention include bacteria, yeast, filamentous fungi, plant cells, and animal cells. The host cell is preferably an actinomycete in terms of introduction and expression efficiency.
Example actinomycetes include Rhodococcus and Nocardia bacteria. The actinomycete is preferably, for example, Rhodococcus erythropolis, Rhodococcus rhodochrous, Rhodococcus wratislaviensis, or Nocardia globerula. The host cell is particularly preferably Rhodococcus erythropolis as in the Examples below.
For an embodiment of the present invention, the transformant preferably further includes:
The electron transport chain protein is not limited to any particular one. Examples include the electron transport chain protein described under <2. Monooxygenase reaction system>.
The transporter protein may be any protein having the function of uptake, into the transformant, of a substance that is to serve as a substrate of the monooxygenase.
Examples of the transporter protein include a permease (for example, a symporter, an antiporter, or a uniporter) and an ABC transporter.
For an embodiment of the present invention, the transporter protein is preferably a protein selected from the group consisting of (q) to (t) below,
The protein of (q) above is a protein comprising the amino acid sequence represented by SEQ ID NO: 5, and is derived from Rhodococcus wratislaviensis. SEQ ID NO: 5 represents a polypeptide comprising 480 amino acid residues in total, the polypeptide having a Protein ID of “peg.800” labeled in Protein Discover Software (available from Thermo Scientific).
The protein of (r) above is, for example, a functionally equivalent mutant, derivative, variant, allele, homolog, ortholog, or partial peptide of a protein comprising the amino acid sequence represented by SEQ ID NO: 5 or a fusion protein produced from the above protein and another protein or peptide. The protein of (r) is not limited in terms of the detailed sequence as long as it has transport activity.
The protein of (s) above is also intended to be, for example, a functionally equivalent mutant, derivative, variant, allele, homolog, ortholog, or partial peptide of a protein comprising the amino acid sequence represented by SEQ ID NO: 5 or a fusion protein produced from the above protein and another protein or peptide. The protein of (s) is not limited in terms of the detailed sequence as long as it has transport activity.
For the protein of (t) above, SEQ ID NO: 10 represents a base sequence (open reading frame or ORF) of a gene encoding a protein comprising the amino acid sequence represented by SEQ ID NO: 5.
For the present embodiment, the transporter protein is not limited to a protein selected from the group consisting of (q) to (t) above, and may be another protein involved with substance transport on a cell membrane.
For general descriptions of a gene and proteins (for example, term definitions), reference is made to the descriptions under <1. Monooxygenase>.
The transformant including (1) a gene encoding an electron transport chain protein promotes provision of oxidation-reduction power for the monooxygenase and thereby advantageously allows a β-hydroxyamino acid to be produced efficiently.
The above (1) a gene encoding an electron transport chain protein functions to, in a case where a host/transformant into which the gene is to be introduced does not have an electron transport chain protein for providing oxidation-reduction power for the monooxygenase, compensate for the lack of an electron transport chain protein and in a case where a host/transformant into which the gene is to be introduced does have an electron transport chain protein for providing oxidation-reduction power for the monooxygenase, enhance the provision of oxidation-reduction power.
The transformant including (2) a gene encoding a transporter protein promotes uptake of a monooxygenase substrate into the transformant and thereby advantageously allows a β-hydroxyamino acid to be produced efficiently.
<6. Method for Producing β-hydroxyamino Acid>
An embodiment of the present invention provides a method for producing a β-hydroxyamino acid, the method including the step of culturing the transformant described under <5. Transformant> in a medium including an α-amino acid or α,α-disubstituted amino acid. The production of a β-hydroxyamino acid according to the present embodiment is production involving use of the transformant described under <5. Transformant>, and is not particularly limited in terms of, for example, other specific arrangements, conditions, materials, or equipment for use.
The transformant is preferably an actinomycete, in particular Rhodococcus bacteria. The transformant is preferably Rhodococcus erythropolis among others. Using such bacteria allows a β-hydroxyamino acid to be produced highly efficiently.
For the present embodiment, the production of a β-hydroxyamino acid with use of the transformant is achieved by the presence, in a medium, of both the transformant and an α-amino acid or α,α-disubstituted amino acid that is to serve as a substrate. When to add an α-amino acid or α,α-disubstituted amino acid to a medium is not limited to any particular time. An α-amino acid or α,α-disubstituted amino acid may be added, for example, at the same time as the expression of an introduced gene in the transformant or either or both of before and after the expression of an introduced gene in the transformant. The present embodiment may be arranged such that an α-amino acid or α,α-disubstituted amino acid is added to a medium already including the transformant or that the transformant is put into a medium already including an α-amino acid or α,α-disubstituted amino acid. The conditions are not limited as above, and may be set as appropriate by a person skilled in the art so that a β-hydroxyamino acid can be produced efficiently.
For the present embodiment, the α-amino acid, the α,α-disubstituted amino acid, and the β-hydroxyamino acid may be those described under <1. Monooxygenase>.
Regarding the step of culturing the transformant, a method for culturing a host strain for the transformant may suitably be a conventionally publicly known one, and is not limited to any particular one. The temperature during the culture is, for example, preferably 20° C. to 45° C., more preferably 25° C. to 35° C., as with a usual method. The reaction time is also not limited to any particular length. The culture is preferably 1 hour to 120 hours long, more preferably 24 hours to 72 hours long, from the expression of an introduced gene.
The method for collecting a β-hydroxyamino acid from a culture or bacterial cell may be a method normally used to obtain a microorganism product, and is not limited to any particular one.
The descriptions of items <1> to <6> above are applicable as appropriate to other items as well. The present invention is not limited to the embodiments, but can be altered by a skilled person in the art within the scope of the claims. The present invention also encompasses, in its technical scope, any embodiment derived by combining technical means disclosed in differing embodiments. The following description will discuss the present invention on the basis of Examples. The present invention is, however, not limited to the Examples only.
With use of 2 ml of a liquid medium for accumulation which liquid medium included 0.1% 2-aminoisobutyric acid, 0.1% ammonium chloride, 0.1% potassium dihydrogenphosphate, 0.1% dipotassium hydrogenphosphate, 0.03% magnesium sulfate heptahydrate, and 0.01% Difco Yeast Nitogen Base w/o Amino Acids and Ammoniumu Sulfate, various samples of soil collected from the natural world were shake-cultured at 28° C. for 5 days (the concentration is expressed in (w/v)% [the same applies throughout the Examples]). A culture solution in which a microorganism was starting to grow was inoculated into 2 ml of fresh liquid medium for accumulation. After this operation was carried out several times, a 2-aminoisobutyric acid-utilizing microorganism was isolated from a 1.5% agar plate medium prepared with 1.5% agar plate medium containing the same components as the above liquid medium. Each isolated microorganism was inoculated again in 2 ml of a liquid medium for accumulation, and was shake-cultured at 28° C. for 5 days. Then, a centrifugal operation was carried out at 8000 g for 10 minutes to collect bacteria. The bacteria were washed twice with a 0.85% saline solution. The wet cell was used for a resting microorganism reaction below. The resting microorganism reaction was carried out by shaking the mixture of 10 mM of 2-aminoisobutyric acid, 10 mM of glucose, 1 mM of aminooxyacetic acid, and 5% wet cell in 50 mM of HEPES buffer (pH 7.5) at 300 rpm for 4 hours.
The results are shown in Table 1. Table 1 indicates production of α-methyl-D-serine in three kinds of microorganisms.
Rhodococcus
wratislaviensis
Rhodococcus
wratislaviensis
Nocardia
globerula
11 nmol of MeSer per min per mg of wet cell
2Enantiomeric excess of α-methyl-D-serine
<Analysis Conditions>
An amino acid in an analysis solution was derivatized with use of AccQ-Tag derivation kit (Nihon Waters K.K.), and was then subjected to LCMS analysis.
R. wratislaviensis C31-06 strains were each cultured at 28° C. for 38.5 hours with use of 250 ml of 2-aminoisobutyric acid-induced liquid medium (0.1% 2-aminoisobutyric acid, 0.1% ammonium chloride, 0.1% potassium dihydrogenphosphate, 0.1% dipotassium hydrogenphosphate, 0.03% magnesium sulfate heptahydrate, and 0.01% Difco Yeast Nitogen Base w/o Amino Acids and Ammoniumu Sulfate) or 250 ml of a non-induced medium (which was identical to a 2-aminoisobutyric acid-induced liquid medium except that 0.1% 2-aminoisobutyric acid was replaced with 0.05% glucose) (for each, n=3). Each cultured bacterial cell was collected through centrifugation at 4° C. and 8000 g for 10 minutes, and was suspended in 50 mM of a Tris-HCl (pH8.0) buffer including 7M of urea, 2.0 mM of thiourea, 2% CHAPS, 10 mM of dithiothreitol, and 1 tablet/10 ml of protease inhibitor (Complete Mini, Roche). Then, 0.10-mm beads were added. The bacterial cell was crushed with use of Multi Beads Shocker. Then, the bacterial cell was centrifuged at 4° C. and 20000 g for 15 minutes. The centrifugal supernatant obtained was used as a cell lysate. The precipitate was washed with a minimum amount of 200 mM of TEAB buffer (pH 8.0). The supernatant and the cell lysate together were filtered through a 0.45 μm filter. Next, the filtrate was substituted with 200 mM TEAB buffer. Then, 9.5 mM of tris(2-carboxyethyl)phosphine was added to the substituted filtrate for treatment at 55° C. for 60 minutes. After that, iodoacetamide was added in an amount of 17.9 mM for treatment at room temperature for 30 minutes. Finally, cold acetone was added in an amount 2 to 4 times larger for treatment at −20° C. for 3 hours. The resulting product was centrifuged at 4° C. and 13000 g for 10 minutes for collection of protein. The remaining acetone was removed through treatment at 37° C. for 2 minutes.
Next, tryptic digestion of the protein was carried out. Specifically, the collected protein was suspended in 200 mM of TEAB buffer, and was then digested with use of 47.6 ng/μl of trypsin at 37° C. overnight. After that, the resulting digest was labeled in 41 μl of acetonitrile with use of tandem mass tag (TMT) 6-plex labeling kit (Thermo Fisher Scientific). The digest reacted at room temperature for 60 minutes. Then, 8 μl of 5% hydroxylamine was added, and was mixed for 15 minutes. Next, the liquid was evaporated in a vacuum. Then, the remainder was dissolved in 100 μl of 0.1% trifluoroacetic acid.
The resulting protein having undergone tryptic digestion was subjected to LCMS analysis (Prominence Nano Flow System [Shimadzu Corporation]). The induced protein was identified with use of the mass spectrometry data obtained and Protein Discover Software (Thermo Scientific) including a protein database prepared on the basis of genomic information for the R. wratislaviensis C31-06 strain (obtained from Hokkaido System Science). The results are shown in Table 2.
<Analysis Conditions>
The proteins obtained in Example 2 and having Protein ID peg.801-804 were each expected to be a complex for catalyzing a 2-aminoisobutyric acid hydroxylation reaction. Thus, a gene encoding the protein was obtained as below.
Specifically, PCR was carried out under the PCR conditions below to obtain PCR products for peg.801-804.
<PCR Conditions>
The PCR product was inserted, with use of NEBuilder HiFi DNA Assembly Master Mix (New England BioLabs), into a vector pTipQC1 (Hokkaido System Science) treated with restriction enzymes NcoI and HindIII. Next, E. coli JM109 was transformed with use of the plasmid pQAH1. The transformant was cultured at 28° C. overnight in 2 ml of LB medium (including 50 μg/ml of ampicillin). pQAH1 was obtained from the bacterial cell, and then Rhodococcus erythropolis L88 (Hokkaido System Science) was transformed with use of the plasmid. The transformant was cultured at 28° C. overnight in 2 ml of LB medium (including 20 μg/ml of chloramphenicol). Part of the culture solution was added to 2 ml of fresh LB medium (including 20 μg/ml of chloramphenicol), and was shake-cultured at 28° C. After the turbidity of the culture solution reached 0.8 (absorption wavelength: 600 nm), thiostrepton was added at a concentration of 0.2 μg/ml for the purpose of inducing expression of a protein. Next, 2-aminoisobutyric acid was added at a concentration of 10 mM as a reactive substrate. Shaking reaction was then started.
As a result, after 48 hours of reaction, production of 2.7 mM of α-methyl-D-serine was determined.
The above operation showed that peg.801-804 formed a complex for catalyzing a 2-aminoisobutyric acid hydroxylation reaction.
<Analysis Conditions>
An amino acid in an analysis solution was derivatized with use of AccQ-Tag derivation kit (Nihon Waters K.K.), and was then subjected to LC analysis.
[4.1]
A transformed actinomycete that expresses the proteins with Protein ID peg.801, 802, 803 was developed as below.
Specifically, PCR was carried out under the PCR conditions below to obtain PCR products for peg.801, 802, 803.
<PCR Conditions>
The PCR product was inserted, with use of NEBuilder HiFi DNA Assembly Master Mix (New England BioLabs), into a vector pTipQC1 (Qiagen) treated with restriction enzymes NcoI and HindIII. Next, E. coli JM109 was transformed with use of the plasmid pQAH-d804. The transformant was cultured at 28° C. overnight in 2 ml of LB medium (including 50 μg/ml of ampicillin). pQAH-d804 was obtained from the bacterial cell, and then Rhodococcus erythropolis L88 (Hokkaido System Science) was transformed with use of the plasmid. The transformant was cultured at 28° C. overnight in 2 ml of LB medium (including 20 μg/ml of chloramphenicol). Part of the culture solution was added to 2 ml of fresh LB medium (including 20 μg/ml of chloramphenicol), and was shake-cultured at 28° C. After the turbidity of the culture solution reached 0.8 (absorption wavelength: 600 nm), thiostrepton was added at a concentration of 0.2 μg/ml for the purpose of inducing expression of a protein. Next, 2-aminoisobutyric acid was added at a concentration of 10 mM as a reactive substrate. Shaking reaction was then started.
As a result, after 48 hours of reaction, production of α-methyl-D-serine was not determined in the culture supernatant.
The results of Example 3 and the above results show that hydroxylation activity expression requires the peg.804 protein.
[4.2]
Subsequently, a transformed actinomycete that expresses the proteins with Protein ID peg.801, 802, 804 was developed as below.
Specifically, PCR was carried out under the PCR conditions below to obtain PCR products for peg.801, 802, 804.
<PCR Conditions>
Two kinds of PCR products were each inserted, with use of NEBuilder HiFi DNA Assembly Master Mix (New England BioLabs), into a vector pTipQC1 (Qiagen) treated with restriction enzymes NcoI and HindIII. Next, E. coli JM109 was transformed with use of the plasmid pQAH-d803. The transformant was cultured at 28° C. overnight in 2 ml of LB medium (including 50 μg/ml of ampicillin). pQAH-d803 was obtained from the bacterial cell, and then Rhodococcus erythropolis L88 (Hokkaido System Science) was transformed with use of the plasmid. The transformant was cultured at 28° C. overnight in 2 ml of LB medium (including 20 μg/ml of chloramphenicol). Part of the culture solution was added to 2 ml of fresh LB medium (including 20 μg/ml of chloramphenicol), and was shake-cultured at 28° C. After the turbidity of the culture solution reached 0.8 (absorption wavelength: 600 nm), thiostrepton was added at a concentration of 0.2 μg/ml for the purpose of inducing expression of a protein. Next, 2-aminoisobutyric acid was added at a concentration of 10 mM as a reactive substrate. Shaking reaction was then started.
As a result, after 48 hours of reaction, production of α-methyl-D-serine was not determined in the culture supernatant.
The results of Example 3 and the above results show that hydroxylation activity expression requires the peg.803 protein.
A transformed E. coli that expresses the proteins with Protein ID peg.801-804 was developed as below.
Specifically, PCR was carried out under the PCR conditions below to obtain PCR products for peg.803, 804.
<PCR Conditions>
The PCR product was inserted, with use of NEBuilder HiFi DNA Assembly Master Mix (New England BioLabs), into a vector pQE60 (Qiagen) treated with restriction enzymes NcoI and HindIII. Next, E. coli JM109 was transformed with use of the plasmid pQEHyd. The transformant was cultured at 28° C. overnight in 2 ml of LB medium (including 50 μg/ml of ampicillin). Next, part of the culture solution was added to 250 ml of TB medium (including 50 μg/ml of ampicillin), and was shake-cultured at 28° C. After the turbidity of the culture solution reached 0.6 (absorption wavelength: 600 nm), IPTG was added at a concentration of 1 mM for the purpose of inducing expression of a protein. After 16 hours of culture, 2-aminoisobutyric acid was added at a concentration of 10 mM as a reactive substrate. Shaking reaction was then started.
As a result, after 48 hours of reaction, production of 0.2 mM of α-methyl-D-serine was determined. This amount of production of α-methyl-D-serine was smaller than in Example 3.
This indicates that as a host for this reaction system, Rhodococcus bacteria allow higher reactivity than E. coli.
The protein obtained in Example 2 and having Protein ID peg.800 was expected, on the basis of the result of homology search, to be a transporter of 2-aminoisobutyric acid. Thus, a gene encoding the protein with Protein ID peg.800 was obtained as below.
Specifically, PCR was carried out under the PCR conditions below to obtain a PCR product for peg.800.
<PCR Conditions>
The PCR product was inserted, with use of NEBuilder HiFi DNA Assembly Master Mix (New England BioLabs), into a vector pTipRT2 (Hokkaido System Science) treated with restriction enzymes NdeI and HindIII. Next, E. coli JM109 was transformed with use of the plasmid pRAT1. The transformant was cultured at 28° C. overnight in 2 ml of LB medium (including 50 μg/ml of ampicillin). pRAT1 was obtained from the bacterial cell, and then pQAH1 Rhodococcus erythropolis L88 produced in Example 3 was transformed with use of the plasmid. The transformant (pQAH1/pRAT1 Rhodococcus erythropolis L88) was cultured at 28° C. overnight in 2 ml of LB medium (including 5 μg/ml of tetracycline, 20 μg/ml of chloramphenicol). Part of the culture solution was added to 2 ml of fresh LB medium (including 5 μg/ml of tetracycline, 20 μg/ml of chloramphenicol), and was shake-cultured at 28° C. After the turbidity of the culture solution reached 0.8 (absorption wavelength: 600 nm), thiostrepton was added at a concentration of 0.2 μg/ml for the purpose of inducing expression of a protein. Next, 2-aminoisobutyric acid was added at a concentration of 10 mM as a reactive substrate. Shaking reaction was then started.
As a result, after 48 hours of reaction, production of 8.5 mM of α-methyl-D-serine was determined in the culture supernatant.
This Example resulted in determination of a larger amount of product than in Example 3. This indicates that the peg.800 protein improves the reactivity.
The α-methyl-D-serine produced had an optical purity of 93.5% e.e.
<Analysis Conditions>
The optical purity was analyzed with use of the product of mixing 25 μl of reaction solution with 25 μl of 0.8% triethylamine in acetonitrile solution and derivatizing the mixture with 50 μl of 2,3,4,6,-tetra-O-acetyl-β-D-glucopyranosyl isocyanate.
pQAH1/pRAT1 Rhodococcus erythropolis L88 was cultured in an LB medium by a method similar to that for Example 5. Expression of a protein was induced with 0.2 μg/ml of thiostrepton, and then 10 mM of each of L-isovaline, D-isovaline, L-aminobutyrate, and D-aminobutyrate was added together with 5% glucose. After 26 hours of reaction, the reaction supernatant was analyzed by the LCMS analysis method used for Example 1.
As a result, a product was determined of which the molecular weight was increased by 16 for each substrate. This indicates that a hydroxylation reaction was proceeding. The results of NMR and optical rotation analyses showed production of (2S,3S)-2-methyl threonine for a case where L-isovaline was a substrate, (2R,3R)-2-methyl threonine for a case where D-isovaline was a substrate, L-allo-threonine for a case where L-aminobutyrate was a substrate, and D-allo-threonine in a case where D-aminobutyrate was a substrate.
The results of NMR for (2S,3S)-2-methyl threonine and (2R,3R)-2-methyl threonine are as below (Table 3).
A transformed E. coli that expresses the proteins with Protein ID peg.803, 804 was developed as below.
Specifically, PCR was carried out under the PCR conditions below to obtain PCR products for peg.803, 804.
<PCR Conditions>
The PCR product was inserted, with use of NEBuilder HiFi DNA Assembly Master Mix (New England BioLabs), into a vector pQE80 (Qiagen) treated with restriction enzymes BamHI and HindIII. Next, E. coli Rosetta 2 (DE3) was transformed with use of the plasmid pQE804-803. The transformant was cultured at 28° C. overnight in 2 ml of LB medium (including 50 μg/ml of ampicillin, 25 μg/ml of chloramphenicol). Part of the culture solution was added to 200 ml of TB medium (including 50 μg/ml of ampicillin, 25 μg/ml of chloramphenicol), and was shake-cultured at 20° C. After the turbidity of the culture solution reached 0.6 (absorption wavelength: 600 nm), IPTG was added at a concentration of 0.5 mM for the purpose of inducing expression of a protein. After 16 hours of culture, the bacterial cell was recovered through centrifugation, and was washed twice with 0.85% NaCl. The bacterial cell was suspended in 0.5 M of NaCl, 30 mM of imidazole, and 20 mM of HEPES (pH 8.0), and was homogenized ultrasonically. The supernatant of the homogenate as centrifuged was introduced into HisTALON Superflow (1.6×2.5 cm) (Takara Bio Inc.), and was eluted with use of 0.5 M of NaCl, 30 mM of imidazole, and 150 mM of HEPES (pH 8.0) for recovery of an enzyme fraction including peg.803, 804. The enzyme fraction was concentrated through ultrafiltration, and was then introduced into a Superdex 200 Increase 10/300 GL column (1.0×30 cm) (GE Healthcare). Then, the respective molecular weights of the proteins with peg.803, 804 were measured at approximately 180,000 with use of 10 mM of HEPES (pH 8.0) and 0.14M of NaCl. The respective assumed molecular weights of the proteins with peg.803, 804 are 42,000 and 43,000, respectively. This result and the results of the SDS-PAGE analysis indicate that the proteins with peg.803, 804 are associated with each other in an equimolar manner.
This suggests that the monooxygenase includes the proteins with peg.803 and peg.804 and has a heterotetramer structure as a whole.
A transformed E. coli that expresses the protein with Protein ID peg.801 was developed as below.
Specifically, PCR was carried out under the PCR conditions below to obtain a PCR product for peg.801.
<PCR Conditions>
The PCR product was inserted, with use of NEBuilder HiFi DNA Assembly Master Mix (New England BioLabs), into a vector pQE80 (Qiagcn) treated with restriction enzymes BamHI and HindIII. Next, E. coli Rosetta 2 (DE3) was transformed with use of the plasmid pQE-801. The transformant was cultured at 28° C. overnight in 2 ml of LB medium (including 50 μg/ml of ampicillin, 25 μg/ml of chloramphenicol). Part of the culture solution was added to 200 ml of TB medium (including 50 μg/ml of ampicillin, 25 μg/ml of chloramphenicol), and was shake-cultured at 20° C. After the turbidity of the culture solution reached 0.6 (absorption wavelength: 600 nm), IPTG was added at a concentration of 0.5 mM for the purpose of inducing expression of a protein. After 16 hours of culture, the bacterial cell was recovered through centrifugation, and was washed twice with 0.85% NaCl. The bacterial cell was suspended in 0.5 M of NaCl, 30 mM of imidazole, and 20 mM of HEPES (pH 8.0), and was crushed ultrasonically. The supernatant of the crushed liquid as centrifuged was introduced into HisTALON Superflow (1.6×2.5 cm) (Takara Bio Inc.), and was eluted with use of 0.5 M of NaCl, 30 mM of imidazole, and 150 mM of HEPES (pH 8.0) for recovery of an enzyme fraction including peg.801. The enzyme fraction was concentrated through ultrafiltration, was then introduced into a MonoQ 10/100 GL column (1.0×10 cm) (GE healthcare), and was eluted with use of 1M of NaCl and 20 mM of Tris-HCl buffer (pH 7.4). This produced a purified enzyme of peg.801. Then, 0.77 μg/ml of the purified enzyme of peg.801 was added to a reaction solution including 10-150 μM of NADH or NADPH, 20-100 μM of dichloroindophenol, and 100 mM of a potassium phosphate buffer (pH 7.5) for measurement of the enzyme activity of the purified enzyme of peg.801.
The Km value for this reaction was measured at 8.2 μM for NADH and 6.2 mM for NADPH. This shows that peg.801 requires NADH as a coenzyme.
The present invention is applicable to fields that require stable protein supplies, for example, the field of peptide medicine production.
[Accession Number]
NITE BP-02370
[Sequence Listing]
| Number | Date | Country | Kind |
|---|---|---|---|
| 2017-071338 | Mar 2017 | JP | national |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/JP2018/013363 | Mar 2018 | US |
| Child | 16584734 | US |
